The Ministry of Health has launched investigations into the growing misuse of Ozempic, a diabetes drug increasingly used by Kenyans for weight loss instead of its intended medical purpose.
Health Principal Secretary Mary Muthoni confirmed the probe on Thursday, stating that the Pharmacy and Poisons Board (PPB) is handling the matter after health experts raised concerns over its off-label use.
Ozempic, primarily prescribed for Type 2 diabetes, has gained popularity for its weight-reducing effects, raising fears of shortages and potential harm to patients who rely on it for diabetes management.
“We’ve observed with concern the increasing trend of misuse. This is a serious issue, and investigations are underway,” PS Muthoni said.
Initially approved by U.S. health authorities for both diabetes and weight management, the drug has been widely promoted by celebrities globally and locally, fueling its demand in Kenya. Some users are reportedly turning to it without medical supervision, unaware of the risks involved.
Health professionals caution that while Ozempic and other GLP-1 medications can be effective for managing obesity under proper guidance, unsupervised use can lead to dangerous side effects such as hypoglycemia, and in severe cases, life-threatening conditions like ketosis.
There are also emerging concerns about possible mental health impacts from prolonged or inappropriate use, though further studies are still ongoing.
The Ministry has urged Kenyans to seek professional medical advice before using such drugs and warned that regulatory action may follow if misuse continues.
